Lack of efflux mechanism in a clinical isolate of Pseudomonas aeruginosa highly resistant to β-lactams and imipenem

Folia Microbiologica

Volumn 48, Issue 4, 2003, Pages 529-533

  Kadry, A A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS); PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0141567714     PISSN: 00155632     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02931336     Document Type: Article

References (24)

1. ARRET B., JOHNSON D.P., KIRSHBARAUM A.: Outline of details of microbiological assays of antibiotics: second revision. J.Pharm.Sci. 60, 1689-1694 (1971).
2. BUSCHER K.H., CULLMANN W., OPFERKUCH W.: Resistance of P. aeruginosa to imipenem is independent of β-lactamase production. J.Antimicrob.Chemother. 19, 699-706 (1987a).
3. BUSCHER K.H., CULLMANN W., DICK W., OPFERKUCH W.: Imipenem resistance in P. aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob.Agents Chemother. 31, 703-708 (1987b).
4. CHEN H.Y., YUAN M., IBRAHIM-ELMAGHOUL I.B., LIVERMORE D.M.: National survey of susceptibility to antimicrobials amongst clinical isolates of P. aeruginosa. J.Antimicrob.Chemother. 35, 521-534 (1995).
5. GIORDANO A., MAGNI A., TRANCASSINI M., CIPRIANI P.: Outer membrane of proteins and lipopolysaccharide changes after exposure of P. aeruginosa to antibacterial drugs. Microbiologica 16, 281-286 (1993).
6. HUPKOVÁ M., BLAHOVÁ J., BABALOVÁ M., KRČMÉRY V., SCHAFER V.: Transferable resistance to imipenem in hospital isolates of P. aeruginosa. J.Chemother. 5, 14-16 (1993).
7. KISKA D.L., GILLIGAN P.H.: Pseudomonas, pp. 517-525 in P.R. Murry, E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken (Eds): Manual of Clinical Microbiology, 7th ed. American Society for Microbiology, Washington (DC) 1999.
8. KNOTHE H., ANTAL M., KRČMÉRY V.: Imipenem and ceftazidime resistance in P. aeruginosa and K. pneumoniae. J.Antimicrob.Chemother. 19, 136-138 (1987).
9. KÖHLER T., HAMZEHPOUR M.M., EPP S.F., PECHERE J.C.: Carbapenem activities against P. aeruginosa: respective contributions of OprD and efflux systems. Antimicrob.Agents Chemother. 43, 424-427 (1999).
10. KRČMÉRY V., LESIČKA M., BLAHOVÁ J., SCHAFER V.: Indirect transfer of resistance to imipenem in a strain of P. aeruginosa. J.Chemother. 3, 363-368 (1991).
11. LI X.Z., ZHANG L., POOLE K.: Interplay between the MexAB OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of P. aeruginosa. J.Antimicrob.Chemother. 45, 433-436 (2000).
12. LIVERMORE D.M.: Of Pseudomonas, porins, pumps and carbapenems. J.Antimicrob.Chemother. 47, 247-250 (2001).
13. LIVERMORE D.M.: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worset nightmare? Clin.Infect.Dis. 34, 634-640 (2002).
14. MAJTÁN V., HOŠTACKÁ A., MAJTÁNOVÁ L'., TRUPL J.: Toxinogenicity and markers of pathogenicity of Pseudomonas aeruginosa strains isolated from patients with tumor diseases. Folia Microbiol. 47, 445-449 (2002).
15. MASEDA H., YONEYAMA H., NAKAE T.: Assignment of the substrate-selective subunits of the Mex EF-OprN multidrug efflux pump of P. aeruginosa. Antimicrob.Agents Chemother. 44, 658-664 (2000).
16. MASUDA N., SAKAGAWA E., OHYA S.: Outer membrane proteins responsible for multiple drug resistance in P. aeruginosa. Antimicrob.Agents Chemother. 39, 645-649 (1995).
17. NAKAE T., NAKAJIMA A., ONO T., SAITO K., YONEYAMA H.: Resistance to β-lactam antibiotics in P. aeruginosa due to interplay between the Mex AB-OprM efflux pump and β-lactamase. Antimicrob.Agents Chemother. 43, 1301-1303 (1999).
18. National Committee for Clinical Laboratory Standards (NCCLS): Performance Standards for Antimicrobial Disk Susceptibility Tests and Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Documents M2-A7 and M7-A5. NCCLS, Pennsylvania (USA) 2000.
19. NIKAIDO H.: Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob.Agents Chemother. 33, 1831-1836 (1989).
20. NIKAIDO H.: Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264, 382-387 (1994).
21. PAGANI L., LANDINI P., LUZZARO F., DEBIAGGI M., ROMERO E.: Emergence of cross-resistance to imipenem and other β-lactam antibiotics in P. aeruginosa during therapy. Microbiologica 13, 43-53 (1990).
22. PEDERSEN S.S., PRESSLER T., HOIBY N., BENTZON M.W., KOCH C.: Imipenem/cilastatin treatment of multiresistant P. aeruginosa lung infection in cystic fibrosis. J.Antimicrob.Chemother. 16, 629-635 (1985).
23. SRIKUMAR R., LI X.Z., POOLE K.: Inner membrane efflux components are responsible for β-lactam specificity of multidrug efflux pumps in P. aeruginosa. J.Bacteriol. 179, 7875-7881 (1997).
24. YONEYAMA H., NAKAE T.: Cloning of the protein D2 gene of P. aeruginosa and its functional expression in the imipenem-resistant host. FEBS Lett. 283, 177-179 (1991).